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MAX mutations as a cause of 
hereditary pheochromocytoma
Comino-Méndez et al., Nat Genet 2011; 43: 663–667; doi:10.1038/ng.861
Pheochromocytoma (PCC) is a rare neural crest cell tumor that is 
most often located in the adrenal medulla and frequently causes 
secondary hypertension by oversecretion of catecholamines. 
Around 30–40% of people with PCC have familial cases that 
show dominant autosomal inheritance caused by germline muta-
tions affecting one of nine susceptibility genes: RET, VHL, SDHA, 
SDHB, SDHC, SDHD, SDHAF2, NF1, or TMEM127. There are, 
however, some hereditary cases (<10%) not explained by muta-
tions in these genes. In a recent study, Comino-Méndez et al. 
performed exon sequence analysis of three unrelated individuals 
with hereditary PCC and identified mutations in MAX. MAX is 
the most conserved dimerization partner of the MYC–MAX–
MXD1 network of transcription factors that regulate cell prolif-
eration, differentiation, and apoptosis. The mutations found in 
MAX were predicted to alter the ATG initiation codon, intro-
duce a premature stop signal, and cause exon 4 skipping. The 
authors did not detect these variants in more than 750 popu-
lation-matched control chromosomes. Immunohistochemical 
analysis of the three PCCs carrying MAX mutations showed a 
lack of full-length MAX protein (Figure). They next analyzed 
the tumor DNA and found loss of the wild-type MAX allele in 
all three cases, indicating loss of heterozygosity. To decipher the 
mechanism responsible for the loss of heterozygosity, they carried 
out a genome-wide single-nucleotide polymorphism array analy-
sis for one of the tumors and found copy-neutral homozygosity 
caused by uniparental disomy—that is, when a person receives 
two copies of a chromosome, or part of one, from one parent and 
none from the other parent. Thus, the absence of MAX protein 
in the tumors and loss of heterozygosity caused by uniparental 
disomy supported the involvement of MAX alterations in the dis-
ease. The authors also performed a follow-up study of a selected 
series of 59 cases of PCC and identified five additional MAX 
mutations. Interestingly, the widely used rat PCC cell line PC12 
lacks functional MAX, and its reintroduction in the cells induces 
transcriptional repression and growth-rate reduction. All these 
results suggest that MAX disruption increases cell proliferation, 
that MYC functions as a transcriptional regulator despite absence 
of normally functioning MAX protein, and that MAX is a new 
PCC tumor suppressor gene. Analysis of a larger series of patients 
with PCC should provide additional information about the prev-
alence of MAX mutations and clarify the phenotype associated 
with them—information of critical importance for both genetic 
counseling and genetic testing.
Juan Oliver
Steroid-resistant  
nephrotic syndrome with 
sensorineural deafness
Heeringa et al., J Clin Invest 2011; 121: 2013–2024; doi:10.1172/JCI45693
The clinical syndrome of steroid-resistant nephrotic syndrome 
(SRNS) ranges from the intrauterine-onset severe developmental 
phenotype of diffuse mesangial sclerosis to the childhood-onset 
phenotype of focal segmental glomerulosclerosis. Two-thirds of 
all SRNS cases with onset in the first year of life and about a quar-
ter of all childhood cases are caused by single-gene mutations in 
one of only four genes, NPHS1, NPHS2, LAMB2, and WT1. Since 
the molecular cause of most cases of SRNS is unknown, Heeringa 
et al. performed a total-genome search for linkage to identify 
further causative recessive genes. A genome-wide search for link-
age in 14 different consanguineous families with SRNS led them 
to a region of 6.4 Mb in chromosome 14q24.3. Of seven families 
homozygous at this locus (SRNS2), two families from Turkey 
revealed haplotype sharing, thus restricting the critical genetic 
region to 2.1 Mb under the hypothesis that an ancestor common 
to both families introduced the disease allele (homozygosity by 
descent). This interval contained 32 positional candidate genes. 
Exon sequencing of coenzyme Q10 biosynthesis monooxygenase 
6 (COQ6) yielded six different mutations in COQ6 in 13 individ-
uals from seven families, and each mutation was linked to early-
onset SRNS with sensorineural deafness. Because patients with 
primary coenzyme Q10 (CoQ10) deficiency display nephropathy 
and encephalopathy and have been reported to respond to oral 
CoQ10 supplementation, Heeringa et al. administered CoQ10 to 
two patients with proteinuria. One patient presented with a urine 
Detection of MAX by immunohistochemistry. Top: Negative staining 
of tumor cells in a MAX mutation-positive PCC compared with positive 
stromal cells (arrows). Bottom: Normal adrenal tissue showing MAX-
positive staining.
Co
m
in
o-
M
én
de
z 
et
 a
l./
N
at
 G
en
et
562   Kidney International (2011) 80
journal  c lub
protein–creatinine ratio of 40 mg/mg that declined to 8 mg/mg 
within 2 months of treatment; similar results were obtained in 
the second patient. Analysis of the COQ6 protein in the kidney 
showed it to be almost exclusively in glomeruli, and specifically in 
podocytes (Figure). Interestingly, within podocytes, COQ6 was 
absent from mitochondria, but it was expressed within cellular 
processes and within the Golgi apparatus; non-mitochondrial 
localization and function had previously been described for 
CoQ6. To elucidate COQ6 function in podocytes, the authors 
used small interfering RNA to knock down Coq6 expression in 
vitro and found that it decreased cell growth. Further, morpholino 
oligonucleotide knock-down of Coq6 in zebrafish induced apop-
tosis preferentially in heads and trunks of zebrafish embryos, and 
the apoptosis was partially reversed by CoQ10 treatment.
This study suggests that CoQ10-related forms of SRNS and 
hearing loss can be identified and potentially treated.
Juan Oliver
Effect of medial calcification  
on vascular function in uremia
Sutliff et al., Am J Physiol Renal Physiol 2011; 301: F78–F83; doi:10.1152/
ajprenal.00533.2010
The contribution of medial calcification to vascular dysfunction 
in renal failure is not very well known. Sutliff et al. measured 
vascular function ex vivo in control, noncalcified uremic, and 
calcified uremic aortas from rats with adenine-induced renal 
failure. In this particular model, vascular calcifications are lim-
ited to the media of the arteries. Plasma urea was 16 ± 4, 93 ± 
14, and 110 ± 25 mg/dl, and aortic calcium content was 27 ± 4, 
29 ± 2, and 4946 ± 1616 nmol/mg dry weight, respectively, in 
the three groups. Maximal contraction by phenylephrine (PE) 
or KCl was reduced 53% and 63% in uremic aortas, and sensi-
tivity to KCl, but not to PE, was increased. Maximal relaxation 
to acetylcholine was impaired in uremic aortas (30% versus 
65%), and sensitivity to nitroprusside was also reduced, indicat-
ing some impairment of endothelium-independent relaxation 
as well. None of these parameters differed between calcified and 
noncalcified uremic aortas. However, aortic compliance was 
reduced in calcified aortas, ranging from 17% to 61% depend-
ing on the severity of calcification.
In conclusion, uremic (medial) vascular calcification, even 
when not severe, significantly reduces arterial compliance. Vas-
cular smooth muscle and endothelial function are altered in renal 
failure but are not affected by medial calcification, even when 
severe. Caution must be exercised in extrapolating these results 
to patients with kidney disease. Severe uremia and vascular cal-
cification developed within a month in this model, clearly faster 
than the development of vascular calcification in humans and 
without time for remodeling of the vessel wall that could affect 
vascular function in chronic kidney disease. However, this model 
does demonstrate that medial vascular calcification can signifi-
cantly reduce arterial compliance without affecting the function 
of smooth muscle or endothelium.
Marc De Broe
Renal accumulation of biglycan  
and lipid retention accelerates 
diabetic nephropathy
Thompson et al., Am J Pathol advance online publication, 30 June 2011, 
doi:10.1016/j.ajpath.2011.05.016
Sweet and fat are bad. It is known that hyperlipidemia worsens 
diabetic nephropathy, but the mechanism for the accelerated 
accumulation of lipids in the glomeruli of diabetics remains 
unknown. Now, Thompson et al. provide some indirect evi-
dence for the hypothesis that the well-described excessive dep-
osition of proteoglycans, and especially biglycan, in diabetic 
glomerulosclerosis may represent the link to the concomitant 
lipid deposition. This group previously demonstrated that renal 
proteoglycans have high binding affinity for low-density lipo-
protein (LDL). The aim of their most recent study was to deter-
mine the relative effect of diabetes and hyperlipidemia on renal 
proteoglycan content. Diabetic and nondiabetic LDL receptor-
deficient mice were fed diets containing 0% or 0.12% cholesterol 
for 26 weeks, and then kidneys were analyzed for renal lipid and 
proteoglycan content. Diabetic mice on the high-cholesterol 
diet had accelerated development of diabetic nephropathy with 
elevations in urine albumin excretion, glomerular and renal 
hypertrophy, and mesangial matrix expansion. Renal lipid accu-
mulation was significantly increased by consumption of the 
0.12% cholesterol diet, by diabetes, and especially by both. The 
renal proteoglycans biglycan and decorin were detectable in 
glomeruli, with a significant increase in renal biglycan content 
in diabetic mice on the high-cholesterol diet. Renal biglycan 
and renal apolipoprotein B were colocalized, and regression 
analyses showed a significant relation between renal biglycan 
and renal apolipoprotein B content. On the basis of this associa-
tion, the authors postulate that increased renal biglycan content 
in diabetic nephropathy may contribute to renal lipid accumu-
lation and the development of diabetic nephropathy.
Although their assumption is reasonable, a causal relationship 
and evidence of the significance of this association in the progres-
sion of human diabetic nephropathy are lacking at present.
Detlef Schlöndorff
COQ6 locates in podocytes. In rat renal glomeruli (marked with an 
a-GLEPP1 antibody), a-COQ6-TPEP2-labeled podocyte cytoplasm and 
cell processes (left). COQ6 was expressed in podocytes, whose nuclei 
were marked with a-WT1 (middle), but not in mitochondria, marked with 
a-COXIV (right).
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